Abstract
The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 272-274 |
| Number of pages | 3 |
| Journal | Journal of Nuclear Medicine Technology |
| Volume | 25 |
| Issue number | 4 |
| State | Published - Dec 1997 |
| Externally published | Yes |
Fingerprint
Keywords
- Fluorine-18-fluorodeoxyglucose
- Gamma camera
- Myocardial viability
- Positron emissions
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
Cite this
PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose. / Schraml, Frank V.; Driver, Daniel R.; Randolph, Thomas; Silverman, Eugene D.
In: Journal of Nuclear Medicine Technology, Vol. 25, No. 4, 12.1997, p. 272-274.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PET versus SPECT for determining myocardial tissue viability using fluorine-18-fluorodeoxyglucose
AU - Schraml, Frank V.
AU - Driver, Daniel R.
AU - Randolph, Thomas
AU - Silverman, Eugene D.
PY - 1997/12
Y1 - 1997/12
N2 - The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.
AB - The U.S. Food and Drug Administration regulates the manufacture and distribution of 18F-FDG. Acquisition and use of this radiopharmaceutical for myocardial imaging at our institution required approval by our Institutional Review Board. Our initial objective was to present a scientific validation for use of this radiopharmaceutical in adjudicating the 'viable versus scarred myocardium question,' using either a PET scanner or a gamma camera equipped with 511-keV collimators. We believe that our nuclear medicine colleagues who find themselves in a similar business/legal situation regarding the acquisition and use of 18F-FDG will find this review useful. We reviewed the literature to document the efficacy of 18F-FDG, in general, in assessing myocardial viability. We then did a literature-based comparison of PET scanner methodology versus modified gamma camera methodology for imaging 18F-FDG emissions. Imaging 18F-FDG with a modified gamma camera appears to be an effective alternative to imaging with a standard PET camera for assessing myocardial viability.
KW - Fluorine-18-fluorodeoxyglucose
KW - Gamma camera
KW - Myocardial viability
KW - Positron emissions
UR - http://www.scopus.com/inward/record.url?scp=0031463560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031463560&partnerID=8YFLogxK
M3 - Article
C2 - 9438929
AN - SCOPUS:0031463560
VL - 25
SP - 272
EP - 274
JO - Journal of Nuclear Medicine Technology
JF - Journal of Nuclear Medicine Technology
SN - 0091-4916
IS - 4
ER -